System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Michael Untch is an expert in Oncology at Helios Kliniken (Berlin) (Germany). As of October 2026, ScienceLeadR ranks Michael Untch in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Michael Untch has authored 1,019 publications, the most recent in 2026, and is an investigator in 41 clinical trials, 13 of them ongoing. SLR score: 3,910 (community average: 125). How the SLR is computed.

LeadR Profile

Michael Untch Helios Kliniken (Berlin) Germany
3 910 ScienceLeadR Reputation 3910

Unlock

Register Login
Network Map

Oncology

Subspecialties: Surgery - Dermatology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1986 - 2026
Source: PubMed

Helios Kliniken (Berlin)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1019

Citations

Citations: 80 303 1st author: 94 Last author: 117 Unique author: 11

Main journals

J Clin Oncol 140
Cancer Res 131
Ann Oncol 94
Breast Care (Basel) 69
Geburtshilfe Frauenheilkd 62

Best Journals

Ann Oncol 39
J Clin Oncol 39
Lancet Oncol 11

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer-2026 Update.
PMID 42497646 — breast neoplasms, neoplasms, biomarkers, breast, therapeutics		Breast20261
Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer - Clinical significance of micrometastases: Data from five neoadjuvant studies.
PMID 42566837 — lymph nodes, breast neoplasms, neoplasms, biopsy, neoplasm micrometastasis, lymph, breast, therapeutics, dissection		Breast20260
Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.
PMID 42334791 — epidermal growth factor, growth, breast neoplasms, pharmaceutical preparations, neoplasms, hormones, receptors, growth factor, pharmacology, breast, therapeutics, plasma, pharmacokinetics		Clin Pharmacokinet20260
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026.
PMID 42238803 — breast neoplasms, neoplasms, breast, diagnosis, therapeutics		Breast Care (Basel)20260
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.
PMID 42233150 — breast neoplasms, neoplasms, breast, diagnosis, therapeutics		Breast Care (Basel)20260

Clinical Studies 41

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 30
Phase 2 6
N/A 2
Phase 4 2
Phase 2/Phase 3 1

By status:

Completed 23
Recruiting 9
Active not recruiting 7
Not yet recruiting 2

By type:

Interventional 39
Observational 2

By Monocentric/Multicentric:

monocentric 13
multicentric2to4 1
multicentric5to9 1
multicentricup10 26

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

13 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase Ib III Study of Capivasertib CDK4 6 Inhibitors Fulvestrant as Treatment for Advanced Metastatic HR HER2 Breast Cancer (CAPItello 292)
2023-504997-39-00 — genes, epidermal growth factor, fulvestrant, growth, breast neoplasms, neoplasms, hormones, receptors, growth factor, breast, therapeutics		Phase 3Active not recruiting2021
A Study to Test Inavolisib Treatments in Patients with Early Stage PIK3CA Mutated Breast Cancer
2024-518811-20-00 — safety, breast neoplasms, neoplasms, breast, neoadjuvant therapy, therapeutics		Phase 2Recruiting2025
NoLEEta Phase III non inferiority trial of chemotherapy de escalation in hormone receptorpositive Her2 negative intermediate risk early breast cancer treated with Ribociclib (LEE 011) in the adjuvant setting
2025-520979-13-00 — breast neoplasms, neoplasms, drug therapy, hormones, chemotherapy, adjuvant, breast, chemotherapy		Phase 3Not yet recruiting2025
Clinical trial that compares MK 2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically removed
2023-504918-29-00 — breast neoplasms, neoplasms, drug therapy, respect, hormones, breast, therapeutics, chemotherapy		Phase 3Active not recruiting2024
A Randomized Multicenter Placebo controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2 neu Peptide GLSI 100 (GP2 GM CSF) in HER2 neu Positive Subjects with Residual Disease or High Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab based Therapy (FLAMINGO 01)
2023-504323-25-01 — granulocyte-macrophage colony-stimulating factor, safety, breast neoplasms, polymerase chain reaction, neoplasms, breast, therapeutics, trastuzumab		Phase 3Not yet recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS